Inmune Financial Statements From 2010 to 2022

INMB
 Stock
  

USD 8.18  0.45  5.21%   

Inmune Bio financial statements provide useful quarterly and yearly information to potential Inmune Bio investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Inmune Bio financial statements helps investors assess Inmune Bio's valuation, profitability, and current liquidity needs.
We have found sixty-two available fundamental trends for Inmune Bio, which can be analyzed and compared to other ratios and to its competitors. Make sure you confirm all of Inmune Bio regular market performance against the performance between 2010 and 2022 to make sure the company can sustain itself down the road.
Inmune Bio Average Assets are projected to increase significantly based on the last few years of reporting. The past year's Average Assets were at 83.55 Million. The current year Average Equity is expected to grow to about 74.3 M, whereas Net Income Per Employee is forecasted to decline to (3.3 M).
  
Refresh
Check Inmune Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inmune main balance sheet or income statement drivers, such as Gross Profit of 150.8 K, Operating Expenses of 31.6 M or Revenues of 150.8 K, as well as many exotic indicators such as Long Term Debt to Equity of 0.16, Receivables Turnover of 0.0592 or Accounts Payable Turnover of 0.0728. Inmune financial statements analysis is a perfect complement when working with Inmune Bio Valuation or Volatility modules. It can also supplement various Inmune Bio Technical models. Please see the analysis of Inmune Bio Correlation against competitors.

Inmune Bio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets107.8 M99.9 M24 M
Increasing
Slightly volatile
Cash and Equivalents80.7 M74.8 M14.4 M
Increasing
Slightly volatile
Property Plant and Equipment Net589.3 K726 K260.5 K
Increasing
Slightly volatile
Tax Assets5.9 M5.5 M1.2 M
Increasing
Slightly volatile
Trade and Non Trade Receivables16.6 K16.2 K99.3 K
Decreasing
Slightly volatile
Trade and Non Trade Payables4.1 M3.8 M988.5 K
Increasing
Slightly volatile
Goodwill and Intangible Assets14.8 M14.9 M16.3 M
Decreasing
Slightly volatile
Total Liabilities21.3 M19.7 M3.8 M
Increasing
Slightly volatile
Shareholders Equity86.6 M80.2 M20.2 M
Increasing
Slightly volatile
Accumulated Other Comprehensive IncomeK10001.8 K
Increasing
Stable
Current Assets89.1 M82.6 M16.1 M
Increasing
Slightly volatile
Assets Non Current18.8 M17.3 M16.8 M
Increasing
Slightly volatile
Current Liabilities4.7 M4.4 M1.3 M
Increasing
Slightly volatile
Liabilities Non Current16.6 M15.4 M2.6 M
Increasing
Slightly volatile
Total Debt16.4 M15.2 M2.7 M
Increasing
Slightly volatile
Debt Current86.8 K72 K205.2 K
Decreasing
Slightly volatile
Debt Non Current16.4 M15.2 M2.6 M
Increasing
Slightly volatile
Shareholders Equity USD86.6 M80.2 M20.2 M
Increasing
Slightly volatile
Cash and Equivalents USD80.7 M74.8 M14.4 M
Increasing
Slightly volatile
Total Debt USD16.4 M15.2 M2.7 M
Increasing
Slightly volatile
Accounts Payable4.1 M3.8 M988.5 K
Increasing
Slightly volatile
Receivables5.3 M4.9 M1.2 M
Increasing
Slightly volatile

Inmune Bio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues150.8 K181 K34.8 K
Increasing
Slightly volatile
Selling General and Administrative Expense7.6 M8.8 MM
Increasing
Slightly volatile
Research and Development Expense22.2 M20.5 M4.3 M
Increasing
Slightly volatile
Operating Expenses31.6 M29.3 M7.4 M
Increasing
Slightly volatile
Weighted Average Shares14.1 M16.1 M7.9 M
Increasing
Slightly volatile
Weighted Average Shares Diluted14.1 M16.1 M7.9 M
Increasing
Slightly volatile
Revenues USD150.8 K181 K34.8 K
Increasing
Slightly volatile
Gross Profit150.8 K181 K34.8 K
Increasing
Slightly volatile

Inmune Bio Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow from Financing104 M96.4 M18.7 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities 18.6 M17.2 M7.5 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares87.8 M81.4 M16.1 M
Increasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (10.3 K)(10 K)(2.1 K)
Decreasing
Very volatile
Net Cash Flow or Change in Cash and Cash Equivalents57 M52.8 M10.2 M
Increasing
Slightly volatile
Share Based Compensation5.1 M4.8 M2.2 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Gross Margin0.890.90.9842
Decreasing
Slightly volatile
Asset Turnover0.00180.00180.002
Decreasing
Slightly volatile
Sales per Share0.00930.0110.0024
Increasing
Slightly volatile
Price to Sales Ratio93390916 K
Decreasing
Slightly volatile
Price to Book Value2.722.2692.8788
Increasing
Stable
Debt to Equity Ratio0.270.246(2.1173)
Increasing
Slightly volatile
Current Ratio20.4518.9515.8785
Increasing
Slightly volatile
Book Value per Share4.084.9731.4641
Increasing
Slightly volatile
Tangible Assets Book Value per Share5.585.1721.1198
Increasing
Slightly volatile
Total Assets Per Share6.045.60131.6739
Increasing
Slightly volatile
Receivables Turnover0.05920.05490.0169
Increasing
Slightly volatile
Cash and Equivalents Turnover0.0040.00370.0012
Increasing
Slightly volatile
Accounts Payable Turnover0.07280.06750.019
Increasing
Slightly volatile
Long Term Debt to Equity0.160.160.1769
Decreasing
Slightly volatile
Quick Ratio14.0816.53339.9762
Increasing
Slightly volatile
Net Current Assets as percentage of Total Assets84.4778.29011.8284
Increasing
Slightly volatile
Revenue to Assets0.0020.00185.0E-4
Increasing
Slightly volatile

Inmune Bio Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization187.7 M182 M94.3 M
Increasing
Slightly volatile
Enterprise Value131.3 M112.1 M77.2 M
Increasing
Slightly volatile
Invested Capital21 M19.5 M3.2 M
Increasing
Slightly volatile
Average Equity74.3 M68.8 M22.1 M
Increasing
Slightly volatile
Average Assets90.1 M83.5 M25 M
Increasing
Slightly volatile
Invested Capital Average14.6 M13.5 M2.4 M
Increasing
Slightly volatile
Tangible Asset Value90 M83.4 M16.3 M
Increasing
Slightly volatile
Working Capital84.4 M78.2 M14.8 M
Increasing
Slightly volatile
Revenue Per Employee19.5 K18.1 K4.7 K
Increasing
Slightly volatile

Inmune Fundamental Market Drivers

Short Percent Of Float10.73%
Forward Price Earnings-5.11
Shares Short Prior Month1.18M
Average Daily Volume Last 10 Day88.62k
Average Daily Volume In Three Month137.16k
Date Short Interest29th of April 2022
Fifty Day Average7.25
Two Hundred Day Average11.19

Inmune Upcoming Events

Upcoming Quarterly Report3rd of March 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End3rd of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Inmune Bio Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Inmune Bio income statement, its balance sheet, and the statement of cash flows. Inmune Bio investors use historical funamental indicators, such as Inmune Bio's revenue or net income, to determine how well the company is positioned to perform in the future. Although Inmune Bio investors may use each financial statement separately, they are all related. The changes in Inmune Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inmune Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Inmune Bio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Inmune Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Revenues181 K150.8 K
Revenue to Assets 0.001811  0.001954 
Revenue Per Employee18.1 K19.5 K
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inmune Bio without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Efficient Frontier Now

   

Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inmune Bio using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Inmune Bio Correlation against competitors. Note that the Inmune Bio information on this page should be used as a complementary analysis to other Inmune Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Inmune Stock analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
154.9 M
Quarterly Revenue Growth YOY
39.75
Return On Assets
-0.24
Return On Equity
-0.47
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.